Currently Viewing:
The International Society for Pharmacoeconomics and Outcomes Research
Continuing Forward With Innovation and Progress in US Healthcare
May 22, 2017
Dr Gail Wilensky: Senate Health Bill Will Be to the Left of the House
May 22, 2017
Accounting for Stakeholder Preferences in Value Assessments
May 22, 2017
Dr David M. Cutler Highlights the Importance of Reauthorizing the CHIP Program
May 22, 2017
Negotiating Successful Outcomes-Based Contracts
May 23, 2017
Dr Ilene Hollin: Tailored Approach to Value Assessment Is Necessary
May 23, 2017
Influencing Untreated Individuals Through Their Social Networks
May 23, 2017
Dr Steve Pearson Outlines the Importance of Thresholds on Determining Value
May 23, 2017
The Realities and Challenges of Medicare Negotiating Drug Prices
May 24, 2017
Dr Patricia Danzon: Cost-Effectiveness Thresholds Create Incentive to Develop Better Drugs
May 24, 2017
Gene Therapies Present Great Potential, but Also Ethical and Practicality Challenges
May 24, 2017
Currently Reading
Dr James D. Chambers Talks Future Health Economics Trends He Is Watching
May 24, 2017
Dr David Cutler: Won't Be Easy for Senate Republicans to Create a Healthcare Bill
May 30, 2017
Not Enough Attention Paid to Low Healthcare Spending Growth
June 13, 2017
Dr Steve Pearson's Outlook on the Ongoing Updates to ICER's Value Framework
June 18, 2017
Dr Scott Ramsey on Challenges of Determining Cost Effectiveness of Novel Cancer Treatments
June 19, 2017
Dr David Cutler Discusses Opportunities for Bipartisan ACA Reform
June 20, 2017
Dr Steve Pearson Explains How ICER Price Benchmarks Align Cost With Patient Benefits
June 22, 2017
Dr Gail Wilensky Raises Questions About Medicaid's Matching Grant Structure
June 25, 2017
Dr Scott Ramsey Addresses the Need for Differential Pricing Structures for Drugs
July 02, 2017
Dr Steve Pearson: Patient Perspectives Guide ICER Value Framework Development
July 04, 2017
Dr Gail Wilensky on the Likelihood of Continuing Value-Based Reimbursement Demonstrations
July 06, 2017
Dr David Cutler: Trump Administration's Attention Not on Value-Based Purchasing
July 09, 2017
Dr Steve Pearson on Data Needed to Evaluate Clinical and Economic Effects of New Therapies
July 14, 2017

Dr James D. Chambers Talks Future Health Economics Trends He Is Watching

James D. Chambers, PhD, MPharm, MSc, of Tufts Medical Center was named the 2017 recipient of the Bernie J. O'Brien New Investigator Award at the ISPOR 22nd Annual International Meeting. He highlights the trends he is most looking forward to seeing develop over the next year and the next 5 years.


James D. Chambers, PhD, MPharm, MSc, of Tufts Medical Center was named the 2017 recipient of the Bernie J. O'Brien New Investigator Award at the ISPOR 22nd Annual International Meeting. He highlights the trends he is most looking forward to seeing develop over the next year and the next 5 years.

Transcript

As the winner of the 2017 ISPOR Bernie J. O'Brien New Investigator Award, what trends do you feel will be most important in healthcare over the next year, and the next 5 years?

Well it was very special to win the award. Bernie O'Brien was a leading figure in the ISPOR organization before untimely death. And Bernie actually studied at the same university that I did, and had the PhD advisor that I did: Professor Martin Buxton of health economics research at Brunel University in London. And I was one of Martin's final students, so it was very nice to be able to tell Martin that I was the recipient of the Bernie O'Brien award.

I think that over the next year that we'll see greater discussion around these value frameworks. What I'm excited about and looking forward to, is hopefully within the year, greater clarification of how these value frameworks will be used, and how payers will use them, and how they will inform decision making. Because although I think they're maybe a harbinger of what's ahead in terms of consideration of value in decisions, I think it is still very unclear of how they're actually informing decision making. So over the next year that's something I'm very excited about. And at the ISPOR conference this week, we've seen a lot of discussion about these value frameworks.

Over the next 5 years, that's a tougher question of course, but if I was to choose one thing, it would maybe be outcomes-based contracting. With the introduction of some real important innovations in the pharmaceutical space, and along with that comes the high costs of those innovations, and with the increase in pressures and budgets within payers and within the healthcare system as a whole, I think that outcomes-based contracting, or trying to tie payment to results, is something that has real opportunity to increase the value of care delivery and the use of these high-cost treatments.

I think also with the development of EMR, electronic medical records, I think that provides an opportunity to collect data that will allow us to tailor these risk-sharing agreements or performance-based agreements in a way that really ensures that we're getting value for the money we spend on these new innovations.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up